GCGR/GLP-1R dual agonism is also a focus in the treatment of NASH as it can potentially ameliorate hepatic fat accumulation, steatosis and fibrosis, alongside reductions in bodyweight [29, 30]. The gene discussed is GCGR; the disease is metabolic dysfunction-associated steatohepatitis.